BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 33895182)

  • 1. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.
    Zheng J; Zhou Y; Zhang K; Qi Y; An S; Wang S; Zhao X; Tang YD
    BMC Cardiovasc Disord; 2018 Jul; 18(1):147. PubMed ID: 30012085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score.
    Xin Z; Zhu Y; Wang S; Liu S; Xu M; Wang T; Lu J; Chen Y; Zhao Z; Wang W; Ning G; Bi Y; Xu Y; Li M
    Liver Int; 2020 Apr; 40(4):806-814. PubMed ID: 31820847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study.
    Wang J; Liu S; Cao Q; Wu S; Niu J; Zheng R; Bie L; Xin Z; Zhu Y; Wang S; Lin H; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Xu Y; Li M; Bi Y; Zhao Z
    Front Med; 2022 Oct; 16(5):714-722. PubMed ID: 35507246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
    Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
    Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autonomic dysfunction assessed by EZSCAN and subclinical atherosclerosis.
    Sun J; Zhang Y; Xu B; Lv X; Ding L; Chen Y; Sun W; Lu J; Xu M; Bi Y; Ning G
    J Diabetes; 2014 Sep; 6(5):409-16. PubMed ID: 24506497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study.
    Liu L; Wang C; Deng S; Yuan T; Zhu X; Deng Y; Qin Y; Wang Y; Yang P
    Sci Rep; 2023 Jun; 13(1):9690. PubMed ID: 37322025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults.
    Li Z; He C; Liu Y; Wang D; Lin M; Liu C; Shi X; Chen Z; Li X; Yang S; Li W
    J Atheroscler Thromb; 2020 May; 27(5):418-428. PubMed ID: 31527322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese.
    Huang Y; Bi Y; Xu M; Ma Z; Xu Y; Wang T; Li M; Liu Y; Lu J; Chen Y; Huang F; Xu B; Zhang J; Wang W; Li X; Ning G
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2321-6. PubMed ID: 22814750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease.
    Ozturk K; Dogan T; Celikkanat S; Ozen A; Demirci H; Kurt O; Turker T; Yilmaz Y; Uygun A
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):411-417. PubMed ID: 29309395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study.
    Zhang Y; Xia Z; Cai X; Su X; Jin A; Mei L; Jing J; Wang S; Meng X; Li S; Wang M; Wei T; Wang Y; He Y; Pan Y
    Cardiovasc Diabetol; 2023 Dec; 22(1):342. PubMed ID: 38093371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideal Cardiovascular Health is Inversely Associated with Subclinical Atherosclerosis: A Prospective Analysis.
    Wang L; Niu JY; Zhao ZY; Li M; Xu M; Lu JL; Wang TG; Chen YH; Wang SY; Dai M; Li L; Liu SS; Wang WQ; Xu Y; Bi YF
    Biomed Environ Sci; 2019 Apr; 32(4):260-271. PubMed ID: 31217062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.